Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes)
- 30 July 2011
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 153 (2), 187-194
- https://doi.org/10.1016/j.jconrel.2011.04.005
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFvExperimental and Molecular Pathology, 2010
- Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposomeJournal of Controlled Release, 2010
- HER2‐ and EGFR‐Specific Affiprobes: Novel Recombinant Optical Probes for Cell ImagingChemBioChem, 2010
- Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive TumorsJournal of Immunotherapy, 2009
- Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)Investigational New Drugs, 2009
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews in Therapeutic Drug Carrier Systems, 2009
- HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer TherapyChemMedChem, 2008
- Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared ImagingClinical Cancer Research, 2008
- HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer AgentsJournal of Liposome Research, 2008
- LiposomenDrugs, 1997